• Users Online: 334
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2021  |  Volume : 10  |  Issue : 4  |  Page : 202-207

Burden of comorbidities and their treatment in patients with active tuberculosis: A prospective study


1 Department of Medicine, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India
2 Department of Pharmacology, Seven Hills College of Pharmacy, Tirupati, Andhra Pradesh, India

Correspondence Address:
Venkat Manolasya
Assistant Professor, Department of Medicine, Sri Venkateswara Institute of Medical Sciences, Tirupati 517 507, Andhra Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jcsr.jcsr_8_21

Rights and Permissions

Background: Patients diagnosed to have active tuberculosis (TB) may have co-existing comorbid conditions. Treatment for both conditions may lead to possible drug-related problems. Hence, the present study was designed to understand the incidence and pattern of drug-related problems. This knowledge gives a scope to minimise the occurrence and help patients to adhere to treatment. Methods: A prospective observational study was carried out for a period of 6 months. A pre-designed data collection form was used for this study that was used to document clinical data including brief history, laboratory investigations, treatment details and drug-drug interactions (DIs). Results: One hundred and five TB patients were enrolled in the study. Their mean age was 43.7 ± 16.8 years. Sixty patients were found to have comorbidities. One hundred and fifty-eight drug-related problems between comorbidities' treatment regimens and ATT were documented. DIs were the most common drug-related problems. Seventy-nine major DIs and 74 moderate DIs were documented. Nine patients had adverse drug reactions which were ATT-induced hepatotoxicity, thrombocytopenia and anaemia. Conclusions: Co-existence of comorbidities and their treatment resulted in a significant burden on patients who are diagnosed positive for TB. This can lead to treatment delay or failure or default. Strategies and programmes to tackle the burden of comorbid conditions on TB-positive patients are to be developed and implemented aggressively.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed293    
    Printed0    
    Emailed0    
    PDF Downloaded44    
    Comments [Add]    

Recommend this journal